Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Subject will receive ivonescimab and chemotherapy

Subject will receive pembrolizumab and chemotherapy

Subject will receive ivonescimab and chemotherapy as an IV injection

Ivonescimab Injection

Subject will receive pembrolizumab and chemotherapy as an IV injection

Pembrolizumab Injection

Summit Clinical Trial Information

This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoint is overall survival and key secondary endpoints include progression free survival. response and safety.

Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

Overall Survival (OS) in the ITT population

Progression-free survival (PFS) assessed by investigator based on RECIST v1.1

incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results

Spots Global Cancer Trial Database for ivonescimab injection